Homebiopharmaceutical

biopharmaceutical

Eyenovia Announces FDA Acceptance of New Drug Application for MydCombi(TM) for In-Office Pupil Dilation

Eyenovia Announces FDA Acceptance of New Drug Application for MydCombi(TM) for In-Office Pupil Dilation

December 13, 2022

Arbutus Completes Enrollment in its Phase 2a Clinical Trial Combining AB-729 with NA Therapy and Peginterferon alfa-2a in Patients with Chronic Hepatitis B Virus Infection

Arbutus Completes Enrollment in its Phase 2a Clinical Trial Combining AB-729 with NA Therapy and Peginterferon alfa-2a in Patients with Chronic Hepatitis B Virus Infection

December 13, 2022

ADMA Biologics Announces FDA Approval for Room Temperature Storage of ASCENIV(TM) & BIVIGAM®

ADMA Biologics Announces FDA Approval for Room Temperature Storage of ASCENIV(TM) & BIVIGAM®

December 13, 2022

ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal Fourth Quarter and Year Ended September 30, 2022

ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal Fourth Quarter and Year Ended September 30, 2022

December 13, 2022

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against SolarEdge, Eiger, Unisys, and Rent and Encourages Investors to Contact the Firm

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against SolarEdge, Eiger, Unisys, and Rent and Encourages Investors to Contact the Firm

December 12, 2022

Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Eiger BioPharmaceuticals, Inc. (EIGR)

Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Eiger BioPharmaceuticals, Inc. (EIGR)

December 12, 2022

Corvus Pharmaceuticals Presents Updated Data from CPI-818 (ITK Inhibitor) Phase 1/1b Clinical Trial at the 64th American Society of Hematology (ASH) Annual Meeting & Exposition

Corvus Pharmaceuticals Presents Updated Data from CPI-818 (ITK Inhibitor) Phase 1/1b Clinical Trial at the 64th American Society of Hematology (ASH) Annual Meeting & Exposition

December 12, 2022

Curis Announces Additional Encouraging Clinical Data from TakeAim Leukemia Study of emavusertib (CA-4948) in Monotherapy R/R AML and hrMDS

Curis Announces Additional Encouraging Clinical Data from TakeAim Leukemia Study of emavusertib (CA-4948) in Monotherapy R/R AML and hrMDS

December 12, 2022

Affimed Presents Updated Data for AFM28 Demonstrating Efficient Elimination of Leukemic Stem and Progenitor Cells in Combination with Allogeneic NK cells in Preclinical Models of Acute Myeloid Leukemia and Myelodysplastic Syndrome at the Annual ASH 2022 Meeting

Affimed Presents Updated Data for AFM28 Demonstrating Efficient Elimination of Leukemic Stem and Progenitor Cells in Combination with Allogeneic NK cells in Preclinical Models of Acute Myeloid Leukemia and Myelodysplastic Syndrome at the Annual ASH 2022 Meeting

December 12, 2022

Kaskela Law LLC Announces Shareholder Class Action Lawsuit Against Eiger BioPharmaceuticals, Inc. (EIGR) Encourages Long-Term EIGR Investors to Contact the Firm

Kaskela Law LLC Announces Shareholder Class Action Lawsuit Against Eiger BioPharmaceuticals, Inc. (EIGR) Encourages Long-Term EIGR Investors to Contact the Firm

December 12, 2022

« 1 … 12 13 14 15 16 … 558 »